eFFECTOR Therapeutics, Inc.
Edit

eFFECTOR Therapeutics, Inc.

http://effector.com/
Last activity: 08.06.2023
Categories: InformationProductProductionPublicResearchBioTechCareDevelopmentDrugHealthTech
eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.
Likes
520
Followers
1.32K
Mentions
18
Location: United States, California, San Diego
Employees: 11-50
Phone: +1 858-546-3997
Total raised: $123.6M
Founded date: 2012

Investors 6

Funding Rounds 3

DateSeriesAmountInvestors
24.07.2017Series C$38.6M-
22.12.2015Series B$40M-
20.05.2013Series A$45M-

Mentions in press and media 18

DateTitleDescriptionSource
08.06.2023eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gro...eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules /EIN News...einpresswi...
08.06.2023eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gro...-globenewsw...
10.01.2018Biopharma watchers arrive at rare consensus: 2018 will be bi...Not one person said they expect total M&A activity to decline in the coming year, relative to 20...medcitynew...
24.07.2017 eFFECTOR Therapeutics Raises $38.6M San Diego-based eFFECTOR Therapeutics, a developer of treatments for cancer, has raised $38.6M in a ...socaltech....
24.07.2017eFFECTOR Therapeutics Closes $38.6M Series C FinancingeFFECTOR Therapeutics, Inc., a San Diego, CA-based developer of selective translation regulators for...finsmes.co...
24.07.2017eFFECTOR Therapeutics Inks $38.6M Series C SAN DIEGO, CA, Leader in the development of selective translation regulators for the treatment of ...vcnewsdail...
19.02.2016effector Therapeutics Increases Series B Financing to $56MeFFECTOR Therapeutics, Inc., a San Diego, CA-based biopharmaceutical company developing selective tr...finsmes.co...
19.02.2016Effector Therapeutics bumps up Series B to $56MThe company says that eFT508 can regulate a number of cancer-driving and immune-signaling pathways –...medcitynew...
19.02.2016 eFFECTOR Therapeutics Boosts Series B To $56M San Diego-based eFFECTOR Therapeutics, which is developing gene translation technology to help in th...socaltech....
22.12.2015 eFFECTOR Therapeutics Picks Up $40M For Cancer Treatment...San Diego-based eFFECTOR Therapeutics, a biopharmaceuticals startup focused on treatment of cancer, ...socaltech....
Show more

Reviews 0

Sign up to leave a review

Sign up Log In